Clarithromycin resistance and susceptibility patterns of Mycobacterium avium strains isolated during prophylaxis for disseminated infection in patients with AIDS

Clinical Infectious Diseases

Volumn 27, Issue 4, 1998, Pages 807-812

  Craft, J Carl ^a   Notario, Gerard F ^b   Grosset, Jacques H ^b   Heifets, Leonid B ^b  

^a ABBOTT LABORATORIES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; PLACEBO;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BACTEREMIA; BACTERIUM ISOLATE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; IMMUNE DEFICIENCY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 2442763933     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/514961     Document Type: Article

References (23)

1. Horsburgh CR, Havlik JA, Ellis DA, et al. Survival of patients with acquired immune deficiency syndrome and disseminated Mycobacterium avium complex infection with and without antimycobacterial chemotherapy. Am Rev Respir Dis 1991; 144:577-9.
2. Agins BD, Berman DS, Spicehandler D, El Sadr W, Simberkoff MS, Rahal JJ. Effect of combined therapy with ansamycin, clofazimine, ethambutol, and isoniazid for Mycobacterium avium infection in patients with AIDS. J Infect Dis 1989; 159:734-7.
3. Hawkins CC, Gold JW, Whimbey E, et al. Mycobacterium avium complex infections in patients with acquired immunodeficiency syndrome. Ann Intern Med 1986; 105:184-99.
4. Hoy J, Mijch A, Sandlum M, Grayson L, Lucas R, Dwyer B. Quadruple-drug therapy for Mycobacterium avium intracellulare bacteremia in AIDS patients. J Infect Dis 1990; 161:801-5.
5. Masur H, Tuazon C, Gill V. Effect of combined clofazimine and ansamycin therapy of Mycobacterium avium - Mycobacterium intracellulare bacteremia in patients with AIDS. J Infect Dis 1987; 155:127-9.
6. Wong B, Edwards FF, Kiehn TE, et al. Continuous high-grade Mycobacterium avium intracellulare bacteremia in patients with the acquired immunodeficiency syndrome. Am J Med 1985; 78:35-40.
7. Chiu J, Nussbaum J, Bozzette S, Tilles JG, Young LS, Leedom J. Treatment of disseminated Mycobacterium avium complex infection with amikacin, ethambutol, rifampin, and ciprofloxacin. Ann Intern Med 1990; 113:358-61.
8. Kemper CA, Meng TC, Nussbaum J, Chiu J, Fiegal DF, Bartok AE. Treatment of Mycobacterium avium complex bacteremia in AIDS with a four-drug regimen: rifampin, ethambutol, clofazimine, and ciprofloxacin. Ann Intern Med 1992; 116:466-72.
9. Kemper CA, Havlik D, Haghighat D, Dube M, Bartok AE, Sison JP. The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol, and rifampin, on Mycobacterium avium complex bacteremia in patients with AIDS. J Infect Dis 1994; 170:157-64.
10. Sison J, Yao Y, Kemper C, et al. Treatment of Mycobacterium avium complex infection: do the results of in vitro susceptibility results predict therapeutic outcome in humans? J Infect Dis 1996; 173:677-83.
11. Dautzenberg B, Truffot C, Legris S, et al. Clarithromycin against Mycobacterium avium infection in AIDS patients: a controlled clinical trial. Am Rev Resp Dis 1991; 144:564-9.
12. Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease: a randomized, double-blind, dose-ranging study in patients with AIDS. Ann Intern Med 1994; 121:905-11.
13. Haas DW, Des Prez RM. Mycobacterium tuberculosis. In: Mandell GL, Douglas RG Jr, Bennett JE, eds. Principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone, 1995:2213-43.
14. Heifets L, Mor N, Vanderkolk J. M. avium resistant to clarithromycin and azithromycin. Antimicrob Agents Chemother 1993; 37:2364-70.
15. Fernandes PB, Hardy DJ, McDaniel D, Hanson CW, Swanson RN. In vitro and in vivo activities of clarithromycin against Mycobacterium avium. Antimicrob Agents Chemother 1989; 33:1531-4.
16. Ji B, Lounis N, Truffot-Pernot C, Grosset J. Selection of resistant mutants of Mycobacterium avium in beige mice by clarithromycin monotherapy. Antimicrob Agent Chemother 1992; 36:2839-40.
17. Meier A, Heifets L, Wallace RJ Jr, et al. Molecular mechanism of clarithromycin resistance in Mycobacterium avium: observation of multiple rDNA mutations in a clonal population. J Infect Dis 1996; 174:354-60.
18. Nash KA, Inderleid CB. Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease. Antimicrob Agents Chemother 1995; 39:2625-30.
19. Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996; 335:384-91.
20. Sanches T, Vanderkolk J, Seay S, Heifets L. Quantitation of mycobacteria in blood specimens from patients with AIDS. Tubercle Lung Dis 1994; 75:386-90.
21. Siddiqi SM, Heifets LB, Cynamon MH, et al. Rapid growth macrodilution method for determination of MICs for Mycobacterium avium isolates. J Clin Microbiol 1993; 31:2332-8.
22. SAS Institute, Inc. SAS user's guide: statistics. Version 6 ed. Cary, NC: SAS Institute, 1990.
23. Anonymous. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1997; 46 (RR-12):1-46.